# Cogent Biosciences

Cogent Biosciences is a publicly traded biotechnology company based in Waltham, United States.

## Overview

- **Organization type:** publicly traded biotechnology company
- **Headquarters:** Waltham, United States
- **Region:** North America
- **Address:** 180 Third Avenue, 4th floor, Waltham, MA 02451, United States
- **Assets under management:** Undisclosed
- **Website:** www.cogentbio.com
- **LinkedIn:** https://www.linkedin.com/company/unum-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

Cogent Biosciences is a biotechnology firm based in Cambridge, United States, established in 2014. The company focuses on developing precision therapies for genetically defined diseases. Cogent Biosciences has secured $290 million in total funding.

## Sectors

- Biotech
- Precision Medicine

## Offices

- Boulder, CO, United States

## People

- Andrew Robbins — Chief Executive Officer & President
- Dave Canner — Chief Financial Officer

## Questions

### Who leads investment decisions at Cogent Biosciences?

Andrew Robbins serves as CEO and President. The board of directors includes a founding partner from Fairmount Funds Management. The chief scientific officer oversees discovery and pipeline decisions (firm website).

### How does Cogent Biosciences source its therapeutic candidates?

Cogent's candidates are designed internally by its Boulder-based discovery team, focusing on validated genetic targets. The company does not license or in-license external assets; it develops small-molecule drugs from scratch (firm website).

### What investment stages does Cogent Biosciences typically target?

Cogent operates as a discovery-to-development biotech. It funds early-stage research and preclinical work, aiming to advance candidates through clinical trials on its own. No disclosed partnership or co-development model.

### Which sectors does Cogent Biosciences explicitly avoid?

Cogent focuses solely on small-molecule precision therapies for genetically defined diseases. It does not invest in medical devices, diagnostics, gene therapies, vaccines, or large-molecule biologics.

### How is Cogent Biosciences related to Fairmount Funds?

Fairmount Funds Management LLC has a board representative at Cogent: a founding partner and the director of research serve on Cogent's board of directors. Fairmount is an investment firm, not a parent company.

## Related profiles

- [MUKC Fund I](https://altss.com/profile/mukc-fund-i)
- [SAI Global's Property Division](https://altss.com/profile/sai-globals-property-division)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cogent-biosciences

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology